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Rotavirus vaccination has been a global health success story. In
2008, RotaTeq received World Health Organization (WHO) pre-
qualification, which was followed by the prequalification of
ROTARIX in 2009 [1]. Over the following decade, these two vacci-
nes were introduced in around 100 countries’ immunization pro-
grams and have contributed to significant declines of the global
rotavirus disease burden [2–5]. Then, in 2018, two new rotavirus
vaccines made in India, ROTAVAC and ROTASIIL, also received
WHO prequalification. This was a landmark achievement for the
rotavirus community, as it expands product choice and has the
potential to help lower prices, mitigate supply concerns, and
enhance rotavirus vaccine impact around the world through the
broader use of rotavirus vaccines, particularly in low- and mid-
dle-income countries. However, having a range of rotavirus vaccine
options with heterogeneous characteristics including different pre-
sentations, dosing schedules, and prices can also present decision-
makers with more complex choices in selecting a vaccine product.
This challenge is likely most pressing in countries where rotavirus
burden is highest, resources are particularly constrained, and the
feasibility of fully assessing and comparing all options is most
limited.
Gavi, the Vaccine Alliance, and international partners recog-
nized this challenge and have been working to compile informa-
tion to help country decision-makers evaluate the available
rotavirus vaccine products [1]. These resources include details on
the vaccines’ efficacy, effectiveness, safety, cost, cost-effectiveness,
storage and transportation requirements, and other programmatic
considerations. Despite considerable effort, decision-making
remains challenging for those seeking to optimize rotavirus vac-
cine product choices. Reasons for this difficulty may include the
breadth and depth of the available information, challenges in prior-
itizing different product attributes, the dynamic nature of the rota-
virus vaccine market, the lack of guidance on when and how to
consider product switches and in some cases, interpretation of
the available information.
Cost and cost-effectiveness are important considerations in
making rotavirus vaccine product choices; they also exemplify
some of the challenges that countries face. A recent publication
in this journal (written by the authors of this commentary) com-
pared the costs and cost-effectiveness of three alternative rotavirus
vaccines in three countries supported by Gavi (Bangladesh, Ghana,
and Malawi), assuming common efficacy in each country across
the three products [6]. The analysis concluded that all three rota-
virus vaccines examined were likely to be cost-effective in each
country compared to no vaccination. In addition, one of the prod-
ucts was consistently the least costly and most cost-effective of
the three examined (Table 1). While this finding was consistent
across countries, it was also reported as ‘‘sensitive to relatively
modest changes” in vaccine prices or vaccine delivery costs. In
short, the previously published analysis showed that: (1) all three
vaccines were likely cost-effective compared to no vaccination, (2)
ROTARIX was the least costly and most cost-effective product in
the three examined Gavi-supported countries, and (3) the results
were consistent but sensitive to small changes in input values, in
particular where there is significant uncertainty (e.g. vaccine prices
or vaccine delivery costs).
In less than a year since the publication of this cost-effective-
ness analysis, the reported prices for all three vaccines have chan-
ged, some dramatically. In addition, new information is emerging
on the delivery costs (e.g. administration, cold chain, training) for
the new rotavirus vaccines. While the initial analysis remains an
accurate portrayal of the world at that time and illustrated key
uncertainties that would influence findings, the results no longer
accurately reflect the choices now facing these three countries. In
fact, if the initial analysis had been undertaken with today’s best
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information, all vaccines would remain cost-effective compared to
no vaccination, but the rank order might now be very different.
Table 2 illustrates two additional scenarios using the previously
reported modelling approach and data inputs [6]. We again assume
common efficacy values across products in each country as we do
not believe there is yet enough evidence to differentiate by prod-
uct. Scenario 1 incorporates updated pricing data for ROTAVAC
(five-dose vial, frozen presentation) and ROTASIIL (two-dose vial,
lyophilized presentation) and emerging information from a single
setting outside of our examined countries which suggests that
delivery costs for ROTAVAC are lower than those for ROTARIX by
approximately $0.30, primarily due to lower cold chain costs
[1,7]. Scenario 2 incorporates these changes and assumes that
emerging findings on ROTAVAC delivery costs could also apply to
ROTASIIL. While there are some data to support these scenarios,
evidence remains limited. As such, Table 2 is meant to illustrate
the sensitivity of the results to relatively small changes to input
parameters rather than a clear argument for a single, economically
preferred product across these countries.
There are two important findings from Scenario 1. First, ROTA-
VAC is now projected to be cost-saving in two of the three coun-
tries examined. This means the cost of averted illnesses exceeds
the cost of the vaccination program, so the vaccination program
both enhances health and saves money. Second, ROTAVAC is the
least costly and most cost-effective product in all countries in this
scenario, a result distinct from the previously published analysis.
Scenario 2, however, shows ROTASIIL to also be cost-saving in
two of three countries and suggests ROTASIIL is the least costly
and most cost-effective product in all three countries. In short,
the economically preferred vaccine product is sensitive and subject
to change across relatively similar scenarios.
One might conclude from this revised analysis that economic
information does not enhance rotavirus vaccine product decisions
because the economically preferred product is so sensitive small
changes in key inputs. That interpretation, however, overlooks
the utility of using economic evaluation to identify these sensitive
parameters and millions of dollars that a country might save
through the selection of an economically preferred product. We
argue that economic considerations remain critical to product
choice but require better data on delivery costs and careful consid-
eration of key tradeoffs, especially the interaction of vaccine price,
incremental delivery costs, and the number of doses per course. It
is likely that the least costly product in one country may be the
most expensive for a neighboring country, but we might also see
one product favored by groups of countries. For example, countries
ineligible for Gavi support might favor one product over others and
we may see different trends in the Gavi market.
This commentary avoids specific guidance to countries seeking
to select an economically preferred product but offers a few
thoughts. First, economic considerations should continue to be part
of a product selection criteria and can help identify critical uncer-
tainties that influence results. As this discussion demonstrates,
these choices are not simple, but international partners can help
provide impartial perspective and experience. Second, any of the
prequalified rotavirus vaccines are likely to be cost-effective in
most countries. Assuming products under consideration are afford-
able, which should be assessed, any of the prequalified products
are likely to be good economic choices. However, the ‘‘best” choice
may be highly sensitive to country context including vaccine prices
and delivery costs. Third, a periodic assessment of current product
availability, product characteristics, and prices can help ensure an
effective, affordable, and sustainable rotavirus vaccination
program.
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Table 1
Cost and cost-effectiveness by country and vaccine product, initial analysis.
Bangladesh Ghana Malawi
Cost per DALY*
averted (country
perspective, with
Gavi subsidy)
$61
(ROTARIX);
$153
(ROTAVAC);
$216
(ROTASIIL)
$230
(ROTARIX);
$283
(ROTAVAC);
$358
(ROTASIIL)
$7 (ROTARIX);
$38 (ROTAVAC);
$32 (ROTASIIL)
Total country cost of
vaccination
program with
Gavi subsidy**
$41.6 M
(ROTARIX);
$53.5 M
(ROTAVAC);
$61.7 M
(ROTASIIL)
$67.9 M
(ROTARIX);
$81.5 M
(ROTAVAC);
$100.5 M
(ROTASIIL)
$10.2 M (ROTARIX);
$14.5 M
(ROTAVAC);
$13.5 M (ROTASIIL)
Least costly and most
cost-effective
product
ROTARIX ROTARIX ROTARIX
* Disability adjusted life year.
** All cost and cost-effectiveness estimates in this article incorporate wastage
rates as previously reported [6].
Table 2
Cost and cost-effectiveness by country and vaccine product, subsequent analysis.
Bangladesh Ghana Malawi
Scenario 1: Updated vaccine prices; applying lower delivery costs for
ROTAVAC
Cost per DALY averted
(country
perspective, with
Gavi subsidy)
$76
(ROTARIX);
Cost-saving
(ROTAVAC);
$126
(ROTASIIL)
$249
(ROTARIX);
$220
(ROTAVAC);
$251
(ROTASIIL)
$7 (ROTARIX);
Cost-saving
(ROTAVAC);
$32
(ROTASIIL)
Total country cost of
vaccination program
with Gavi subsidy
$43.6 M
(ROTARIX);
$29.5 M
(ROTAVAC);
$50.0 M
(ROTASIIL)
$72.6 M
(ROTARIX);
$65.3 M
(ROTAVAC);
$73.3 M
(ROTASIIL)
$10.2 M
(ROTARIX);
$7.3 M
(ROTAVAC);
$13.5 M
(ROTASIIL)
Least costly and most
cost-effective
product
ROTAVAC ROTAVAC ROTAVAC
Scenario 2: Updated vaccine prices; applying lower delivery costs for
ROTAVAC and ROTASIIL
Cost per DALY averted
(country
perspective, with
Gavi subsidy)
$76
(ROTARIX);
Cost-saving
(ROTAVAC);
Cost-saving
(ROTASIIL)
$249
(ROTARIX);
$220
(ROTAVAC);
$207
(ROTASIIL)
$7 (ROTARIX);
Cost-saving
(ROTAVAC);
Cost-saving
(ROTASIIL)
Total country cost of
vaccination program
with Gavi subsidy
$43.6 M
(ROTARIX);
$29.5 M
(ROTAVAC);
$28.0 M
(ROTASIIL)
$72.6 M
(ROTARIX);
$65.3 M
(ROTAVAC);
$62.0 M
(ROTASIIL)
$10.2 M
(ROTARIX);
$7.3 M
(ROTAVAC);
$6.4 M
(ROTASIIL)
Least costly and most
cost-effective
product
ROTASIIL ROTASIIL ROTASIIL
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